Use of CFTR modulators in special populations, part 1: Pregnancy and lactation
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26706 ↗At a glance
Übersichtsarbeit in Pediatric Pulmonology, 2023. Written by Joseph Elijah and 2 co-authors. Institution: Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA. Major MEDLINE topics: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis. Cited 12 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: None.
Topics: Stillen
Abstract (original language)
Safety and efficacy data regarding cystic fibrosis transmembrane conductance regulator (CFTR) modulator use in the setting of pregnancy or breastfeeding remains lacking due to exclusion from key trials and lack of multicenter prospective and retrospective studies in the post‐CFTR modulator era. A scoping review of English articles from the period of January 1, 2012, to July 31, 2023, was conducted utilizing PubMed and EmBase databases with the following terms: “special population (pregnancy, lactation, breastfeeding)” AND “ivacaftor OR lumacaftor OR tezacaftor OR elexacaftor”; “cystic fibrosis transmembrane conductance regulator” AND “off label drug use.” Search results were reviewed by title and abstract for duplications and relevance. Relative to pregnancy or breastfeeding, a total of 18 publications were included for review. Majority of case reports and surveys concluded maternal and infant health were preserved throughout gestation. Likewise, breastfeeding infant case reports show possible changes in liver function and lens opacities, though risk may be increased with both in‐utero and breastfeeding exposure. Ivacaftor (IVA) and lumacaftor (LUM) concentrations in fetal cord blood and maternal blood were found to be equivalent. Yet, low concentrations of IVA and LUM were detectable in breastmilk and infant plasma. Current safety data surrounding CFTR modulator use in the setting of pregnancy and lactation is relatively reassuring; however, long‐term safety remains unclear, necessitating ongoing observation, and reporting by care teams. As such, treatment decisions should be individualized and coproduced.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
- School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, Boston, United States.
- Sanofi Medical Affairs, Bridgewater, New Jersey, USA.
- Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan, USA.
ORCID profiles: Joseph Elijah, Hanna Phan
Funding
- None
Cite
APA
Elijah, J., Fitzgerald, L. J., & Phan, H. (2023). Use of CFTR modulators in special populations, part 1: Pregnancy and lactation. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26706
Vancouver
Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 1: Pregnancy and lactation. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26706
BibTeX
@article{Elijah2023,
author = {Elijah, Joseph and Fitzgerald, Linda J and Phan, Hanna},
title = {Use of CFTR modulators in special populations, part 1: Pregnancy and lactation},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26706}
}
EUVIMED